The Role of Nutrition in Macular DegenerationMay 2004
By Dennis L. Gierhard, PhD
|LE Magazine May 2004|
|The Role of Nutrition in Macular Degeneration|
By Dennis L. Gierhard, PhD
Summary and Prediction
A plausible theory is put forward to support others’ speculation that zeaxanthin may be a “critically essential nutrient” for proper eye function and protection.3 This theory suggests a need to change behaviors and increase dietary consumption of fruits and vegetables to decrease age-related degeneration of the eye. Some evidence suggests it may be more difficult to obtain higher levels of zeaxanthin from the diet than of lutein, indicating that supplementation may be desirable. There is good evidence that zeaxanthin is preferred by ocular tissues because it has unique properties and subtle structural differences compared to lutein that make it a better lipophilic antioxidant and photoprotectant.
Dietary supplementation with 3-6 mg/day of zeaxanthin may reduce the risk of contracting degenerative eye diseases. Significantly higher dietary intake of zeaxanthin (not the isomer meso-zeaxanthin) may be important for individuals with high risks for or advanced symptoms of macular degeneration and cataracts. Other health benefits associated with zeaxanthin also have been noted.
In the near future, we can expect more basic research, animal studies, and objective double-blind clinical trials attempting to clearly define zeaxanthin’s importance in degenerative eye diseases. It is likely that high intake of dietary antioxidants and zeaxanthin will be shown to be a factor in reducing the risk and slowing the progression of degenerative eye diseases. Other important phytonutrients are also likely to act synergistically with zeaxanthin in slowing the aging effects in the eye. As science elucidates the most important degenerative mechanisms and genetics shines its light on inheritance issues and mechanisms, supplements will be on the market to address these needs. Looking out a little further in the future, it is likely that cataract prevalence and progression will benefit from combined research on zeaxanthin and advances in the nutritional biochemistry of the eye.33 This advance could have a positive economic impact on growing Medicare expenditures tied to degenerative eye disease. Perhaps the same impact will be seen concerning diabetic complications of the eye and macular degeneration. With nearly 15 million dry macular degeneration sufferers in the US today and more on the way, a decreased incidence and progression rate would be welcome.
Pharmaceutical and biotechnology companies are developing cold laser and angiogenesis inhibitors for treating the ravaging effects of wet macular degeneration.35 Almost all these treatments target single molecules or single pathways to prevent or destroy unwanted blood vessels. While zeaxanthin may be the single most critical nutrient for the eye, its value will most likely be in conjunction with high dietary intake of multiple nutrients. Eventually there will be a convergence of nutritional intervention (to prevent and modulate early insults and stresses of the eye) and sophisticated medical treatments (for very late and aggressive blood vessel growth of wet macular degeneration).
Future generations will be able to see those important things in life. In the meantime, you can eat healthy (lots of fruits and vegetables, decreased fats, and increased fish oil), increase your dietary intake of zeaxanthin and other antioxidants, stop smoking, lose those extra pounds, watch your risk factors for cardiovascular disease, and protect your eyes when in the sun.
About the Author
1. Schalch W. Possible contribution of lutein and zeaxanthin, carotenoids of the macula lutea, to reducing the risk for age-related macular degeneration: a review. HKJ Ophthalmol. 4(1).
2. Seddon JM. Nutrition and age-related eye disease. VNIS Backgrounder. 3(1).
3. Semba RD, Dagnelie G. Are lutein and zeaxanthin conditionally essential nutrients for eye health? Med Hypotheses. 2003 Oct;61(4):165-72.
4. Krinsky NI, Landrum JT, Bone RA. Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye. Annu Rev Nutr. 2003:23:171-201.
5. Krinsky NI. Possible biologic mechanisms for a protective role of xanthophylls. J Nutr. 2002 Mar;132(3):540S–542S.
6. Roche NDI. Available at: http://www.fda.gov/ ohrms/dockets/dockets/95s0316/rpt0096_01.pdf. Accessed February 27, 2004.
7. Snodderly DM. Evidence for protection against age-related macular degeneration by carotenoids and antioxidant vitamins. Am J Clin Nutr. 1995 Dec;62(6suppl): 1448S–1461S.
8. Zaripheh S, Erdman JW Jr. Factors that influence the bioavailability of xanthophylls. J Nutr 2002 Mar;132(2):531S-534S.
9. Mares-Perlman JA, Millen AE, Ficek TL, Hankinson SE. The body of evidence to sup- port a protective role for lutein and zeaxan- thin in delaying chronic disease. Overview. J Nutr. 2002 Mar;132(3):518-524S.
10. Ford ES, Liu S, Mannino DM, Giles WH, Smith SJ. C-reactive protein concentration and concentrations of blood vitamins, carotenoids, and selenium among United States adults. Eur J Clin Nutr. 2003 Sept;57(9)1157-63.
11. Suzuki K, Ito Y, Ochiai J, et al. Relationship between obesity and serum markers of oxidative stress and inflamma- tion in Japanese. Asian Pac J Cancer Prev. 2003 Jul-Sep;4(3):259-66.
12. Granado F, Olmedillo B, Blanco I. Nutritional and clinical relevance of lutein in human health. Br J Nutr. 2003 Sep; 90(3):487-502.
13. Nishino H. Murakosh M Li T, et al. Carotenoids in cancer chemoprevention. Cancer Metastasis Rev. 2002;21(3-4):257-64.
14. Chew BP, Park JS. Carotenoid action on the immune response. J Nutr. 2004 Jan;134(1):257S-261S.
15. Gonzalez S, Astner S, An W, Goukassian D, Pathak MA. Dietary lutein/zeaxanthin decreases ultraviolet B-induced epidermal hyperproliferation and acute inflammation in hairless mice. J Invest Dermatol. 2003 Aug;121(2)399-405.
16. Toyoda Y, Thomson L, Langner A, et al. Effect of dietary zeaxanthin on tissue distri- bution of zeaxanthin and lutein in quail. IOVS. 2002 Apr;43(4):1210-21.
17. Bone RA, Landrum JT, Tarsis SL. Preliminary identification of the human macular pigment. Vision Res. 1985;25(1):1531–5.
18. Bernstein PS, Khachik F, Carvalho LS, Muir GJ, Zhao DY, Katz NB. Identification and quantitation of carotenoids and their metabolites in the tissues of the human eye. Exp Eye Res. 2001 Mar;72(3):215–23.
19. Handelman GJ, Dratz EA, Reay CC, Van Kuijk JG. Carotenoids in the human macula and whole retina. Investig Ophthalmol Vis Sci. 1988 Jun;29:850–5.
20. Bone RA, Landrum JT, Fernandez L, Tarsis SL. Analysis of macular pigment by HPLC: retinal distribution and age study. Invest Ophthalmol Vis Sci. 1988;29(6):843–9.
21. Bone RA, Landrum J, Hime GW, Cains A, Zamor J. Stereochemistry of the human macular carotenoids. IOVS. 1993 May:34(6):2003-40.
22. Seddon JM, Ajani UA, Sperduto RD, et al. Dietary carotenoids, vitamins A, C and E and advanced age-related macular degenera- tion. JAMA. 1994 Nov 9;272(8):1413-20.
23. Wald G. Human vision and the spectrum. Science. 1945;101:653–658.
24. Nussbaum JJ, Pruett RC, Delori F. Historic perspectives: macular yellow pigment. The first 200 years. Retina. 1981 Oct- Dec;1(4):296-310.
25. Yeum KJ, Taylor A, Tang G, Russell RM. Measurement of carotenoids, retinoids, and tocopherols in human lenses. Investig Ophthalmol Vis Sci. 1995 Dec;36(13):2756–61.
26. Lyle BJ, Mares-Perlman JA, Klein BEK, Klein R, Greger JL. Antioxidant intake and risk of incident age-related nuclear cataracts in the Beaver Dam Eye Study. Am J Epidemiol. 1999 May 1;149(1):801–9.
27. Lyle BJ, Mares-Perlman JA, Klein BE, et al. Serum carotenoids and tocopherols and inci- dence of age-related nuclear cataract. Am J Clin Nutr. 1999 Feb;69(2):272–7.
28. Mares-Perlman JA, Lyle BJ, Klein R, et al.Vitamin supplement use and incident cataracts in a population-based study. Arch Ophthalmol. 2000 Nov;118(11):1556-63.
29. Chasan-Taber L, Willett WC, Seddon JM, et al. A prospective study of carotenoid and vitamin A intakes and risk of cataract extrac- tion in US women. Am. J. Clin. Nutr. 1999 Oct;70(4):509–16.
30. Brown L, Rimm EB, Seddon JM, et al. A prospective study of carotenoid intake and risk of cataract extraction in U.S. Men. Am. J. Clin. Nutr. 1999 Oct;70(4):517–24.
31. Jacques PF, Chylack LT Jr, Hankinson SE, et al. Long-term nutrient intake and early age-related nuclear lens opacities. Arch Ophthalmol. 2001 Jul;119(7):1009-19.
32. Berendschot TT, Broekmans WM, Klopping-Ketelaars IA, Kardinaal AF, Van Poppel G, Van Norren D. Lens aging in relation to nutritional determinants and possible risk factors for age-related cataract. Arch Ophthalmol. 2002 Dec;120(12):1732-7.
33. Taylor A. Nutritional and Environmental Influences on the Eye. Boca Raton, FL: CRC Press; 1999:215-50.
34. National Eye Institute. Available at: http://www.nei.nih.gov/. Accessed February 27, 2004.
35. Sun H, Nathans J. The challenge of macular degeneration. Sci Am. 2001Oct;285(4):68-75.
36. Weiter JJ, Delori F, Dorey CK. Central spar- ing in annular macular degeneration. Am J Ophthalmol. 1988 Sep 15;106(3):286–92.
37. Bone RA, Landrum JT, Mayne ST, Gomez CM, Tibor SE, Twaroska EE. Macular pig- ment in donor eyes with and without AMD: a case-control study. Invest Ophthalmol Vis Sci. 2001 Jan;42(1):235–40.
38. Schalch W, Dayhaw-Barker P, Barker FM II. The carotenoids of the human retina. In: Nutritional and Environmental Influences on the Eye. Boca Raton, FL: CRC Press; 1999.
39. Mares-Perlman JA, Fisher AI, Klein R, et al. Lutein and zeaxanthin in the diet and serum and their relation to age-related mac- ulopathy in the Third National Health and Nutrition Examination Survey. Am J Epidemiol. 2001;153:424–432
40. AREDS Research Group. The Age-related Eye Disease Study (AREDS): A Randomized placebo-controlled clinical trial of high-dose supplementation with vitamins C and E, beta carotene and zinc for age-related macular degeneration and vision loss. AREDS Report #8. Arch Ophthalmol. 2001 Oct;119(10):1417-36.
41. Gale CR, Hall NF, Phillips DI, Martyn CN. Lutein and zeaxanthin status and risk of age-related macular degeneration. Invest Opthalmol Vis Sci. 2003 Jun;44(6):2461-5.
42. Sujak A, Gabrielska J, Grudzinski W, Borc R, Mazurek P, Gruszecki WI. Lutein and zeaxanthin as protectors of lipid mem- branes against oxidative damage: the struc- tural aspects. Arch Biochem Biophys. 1999 Nov 15;371(2):301–7.
43. Craft N, Haitema T, Garnett K, Fitch K, Dorey K. Carotenoid, tocopherol, and retinol concentrations in elderly human brain. J Nutr Health and Aging. 2004 (in press).
44. Thomson L, Toyoda Y, Langner A, et al. Elevated retinal zeaxanthin and prevention of light-induced photoreceptor cell death in quail. IOVS. 2002 Nov;43(11):3535-49.
45. Thomson L, Toyoda Y, Delori F, et al. Long term dietary supplementation with zeaxan thin reduces photoreceptor death in light-damaged Japanese quail. Exp Eye Res. 2002 Nov;75(5):529-42.
46. Dorey CK, Cheng KM, Gierhart DL, Craft NE. Dietary manipulation of lens zeaxan- thin in quail. ARVO. 2003;abstract #207/B182.
47. Hammond BR Jr, Johnson EJ, Russell RM, et al. Dietary modification of human macu- lar pigment density. Investig Ophthalmol Vis Sci. 1997 Aug;38(9):1795–801.
48. Garnett KM, Guerra LH, Lamb JD, et al. Serum and macular pigment responses to supplementation with lutein or zeaxanthin. Assoc Res Vis Ophthalmol. 2002;43:2820(abs).
49. Bone RA, Landrum JT, Guerra LH, Ruiz CA. Lutein and zeaxanthin dietary supple- ments raise macular pigment density and serum concentrations of these carotenoids in humans. J Nutr. 2003 Apr;133(4):992-8.
50. Johnson EJ, Hammond BR, Yeum KJ, et al. Relation among serum and tissue concentra- tions of lutein and zeaxanthin and macular pigment density. Am J Clin Nutr. 2000 Jun;71(6):1555–62.
51. Rock CL, Thornquist MD, Neuhouser ML, et al. Diet and lifestyle correlates of lutein in the blood and diet. J Nutr. 2002 Mar;132(3):525S–530S.
52. Olmedilla B, Granado F, Blanco I, Vaquero M, Cajigal C. Lutein in patients with cataracts and age-related macular degenera- tion: a long-term supplementation study. J Sci Food Agric. 2001;81:904–9.
53. Massacesi AL, et al. The effect of oral sup- plementation of macular carotenoids on the prevention of AMD. ARVO 2001;abstract #1261.
54. Olmedilla B, Granado F, Blanco I, Vaquero M. Lutein but not alpha tocopherol supple- mentation improves visual function in patients with age-related cataracts. Nutrition. 2003 Jan;19(1):21-24.
55. Richer SP et al. The lutein antioxidant sup- plementation trial. ARVO 2002;mtg abst #2542.
56. Beatty S, Koh H, Phil M, Henson D, Boulton M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv Opthalmol. 2000 Sep- Oct;45(2):115-34.
57. Ueda T, Ueda T, Fukuda S, et al. Lipid hydroperoxide-induced tumor necrosis fac- tor (tnf) – alpha vascular endothelial growth factor and neovacularization in the rabbit cornea: effect of TNF inhibition. Angiogenesis. 1988;1(2):174-184.
58. Armstrong D, Ueda T, Ueda T, et al. Lipid hydroperoxide stimulates retinal neovascu- larization in rabbit retina through expression of tumor necrosis factor – alpha vascular endothelial growth factor and platelet-derived growth factor. Angiogensesis. 1988;2(1):93-104.
59. Davies NP, Morland AB. Color matching in diabetes: optical density of the crystalline lens and macular pigments. Investig Ophthamol Vis Sci. 2002 Jan; 43(1) 281-9.
60. Nilsson SE, Sundelin SP, Wihlmark U, Brunk UT. Aging of cultured retinal pig- ment epithelial cells: oxidative reactions, lipofuscin formation and blue light damage. Doc Opthalmol. 2003 Jan;106(1):13-6.
61. Khachik F, Bernstein PS, Garland DL. Identification of lutein and zeaxanthin oxidation products in human and monkey retinas. Investing Ophthalmol Vis Sci. 1997 Aug;38(9):1802–11.